表观遗传学市场规模、份额和成长分析（按产品、技术、方法、应用、最终用途和地区）- 产业预测 2025-2032

表观遗传学市场规模预计在 2023 年达到 16 亿美元，并从 2024 年的 18.4 亿美元增长到 2032 年的 55.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 14.8%。

除了 DNA定序之外，市场还在很大程度上受到对基因调控理解的进步的推动，从而增强疾病研究并支持个人化医疗的进步。未来几年，预计投资增加将进一步加速这一成长。然而，全球癌症疫情也带来了挑战，预计2023年将报告约2000万新患者和1000万癌症相关死亡病例，到2040年每年将新增3000万例癌症病例。虽然目前的治疗方法，包括酵素抑制剂和免疫疗法，正在获得关注，但表观遗传疗法作为治疗癌症和神经系统疾病的潜在策略在未来仍具有广阔的前景。总体而言，表观遗传学的巩固和癌症发病率的上升表明未来市场前景强劲。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

表观遗传学市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 套件和试剂
  • 抗体
  • ChIP定序套件
  • 全基因组扩增试剂套件
  • 亚硫酸盐转化试​​剂套件
  • RNA定序套件
  • 5-HMC 和 5-MC 分析套件和试剂
  • 组蛋白
  • 其他的
• 装置
• 酵素
  • DNA修饰酶
  • 蛋白质修饰酶
  • 其他酵素
• 服务

表观遗传学市场规模（依技术及复合年增长率） (2025-2032)

• 市场概况
• DNA甲基化
• 组蛋白甲基化
• 组蛋白乙酰化
• 大型非编码RNA
• 微型RNA修饰
• 染色质结构

表观遗传学市场规模（依方法论和复合年增长率） (2025-2032)

• 市场概况
• NGS
• PCR 和 QPCR
• 质谱分析
• 超音波
• 其他技术

表观遗传学市场规模（按应用和复合年增长率） (2025-2032)

• 市场概况
• 肿瘤学
  • 固态肿瘤
  • 液体肿瘤
• 非肿瘤科 肿瘤科
  • 发炎性疾病
  • 代谢紊乱
  • 感染疾病
  • 心血管疾病
  • 其他的

表观遗传学市场规模（依最终用途和复合年增长率） (2025-2032)

• 市场概况
• 学术研究
• 临床研究
• 医院和诊所
• 製药和生物技术公司
• 其他用户

表观遗传学市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific Inc.（United States）
• Illumina, Inc.（United States）
• Merck KGaA（Germany）
• QIAGEN NV（Netherlands）
• Pacific Biosciences of California, Inc.（United States）
• Bio-Rad Laboratories, Inc.（United States）
• PerkinElmer, Inc.（United States）
• 10x Genomics, Inc.（United States）
• Active Motif, Inc.（United States）
• Zymo Research Corporation（United States）
• New England Biolabs, Inc.（United States）
• Promega Corporation（United States）
• Novartis AG（Switzerland）
• Element Biosciences, Inc.（United States）
• Dovetail Genomics LLC（United States）
• Storm Therapeutics（United Kingdom）

结论和建议

Epigenetics Market size was valued at USD 1.6 billion in 2023 and is poised to grow from USD 1.84 billion in 2024 to USD 5.54 billion by 2032, growing at a CAGR of 14.8% during the forecast period (2025-2032).

The market is poised for significant growth driven by advancements in understanding gene regulation beyond DNA sequencing, which enhances disease research and supports the evolution of personalized medicine. Increased investments are anticipated to further amplify this growth in the coming years. However, the global cancer epidemic poses challenges, with approximately 20 million new cases and 10 million cancer-related deaths reported in 2023, and projections suggesting 30 million cases annually by 2040. Current treatments, including enzyme inhibitors and immunotherapy, are gaining traction, while the future of epigenetic therapy appears promising as a potential leading strategy for addressing cancer and neurological disorders. Overall, the integration of epigenetics and a growing cancer prevalence signal a robust market trajectory ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Epigenetics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Epigenetics Market Segments Analysis

Global Epigenetics Market is segmented by Product, Technology, Technique, Application, End-use and region. Based on Product, the market is segmented into Kits & Reagents, Instruments, Enzymes and Services. Based on Technology, the market is segmented into DNA Methylation, Histone Methylation, Histone Acetylation, Large non-coding RNA, MicroRNA modification and Chromatin structures. Based on Technique, the market is segmented into NGS, PCR & QPCR, Mass Spectrometry, Sonication and Other Techniques. Based on Application, the market is segmented into Oncology and Non-oncology oncology. Based on End-use, the market is segmented into Academic Research, Clinical Research, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies and Other Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Epigenetics Market

A key factor propelling the epigenetics market is the increasing incidence of cancer and various chronic diseases, including cardiovascular conditions. The role of epigenetic modifications, such as DNA methylation and histone alterations, is crucial in the progression of these diseases. This scenario has led to substantial investments in financial and medical advancements, particularly as precision medicine gains traction. Epigenetic therapies are emerging as viable options for personalized treatments, thereby enhancing the demand for epigenetic products and services. As a result, the epigenetics market is experiencing significant growth driven by these evolving healthcare needs and innovations.

Restraints in the Epigenetics Market

While the potential of the epigenetics market is promising, significant obstacles exist that hinder its expansion. A primary challenge is the substantial expense associated with epigenetic research and the development of therapeutic interventions. Conducting epigenetic studies typically necessitates sophisticated technologies and equipment, including next-generation sequencing (NGS) and chromatin immunoprecipitation (ChIP), which can entail high acquisition and operational costs. Consequently, these financial barriers restrict the availability of epigenetic tools and therapies, particularly in developing regions where healthcare budgets are limited, ultimately impeding broader market growth in the field of epigenetics.

Market Trends of the Epigenetics Market

The epigenetics market is witnessing a significant trend driven by advances in epigenetic editing technologies, particularly the emergence of precise CRISPR/Cas9-based tools. These innovations enable researchers to modify epigenetic marks with high specificity, facilitating detailed studies on gene regulation without changing the DNA sequence. As the adoption of these technologies increases, they are poised to transform epigenetic research and unlock new therapeutic avenues, particularly in oncology, neurobiology, and autoimmune conditions. This trend is expected to boost investment in research and development, leading to breakthroughs in understanding complex diseases and enhancing treatment strategies in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Epigenetics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Kits & Reagents
  • Antibodies
  • ChIP sequencing kit
  • Whole Genomic Amplification kit
  • Bisulfite Conversion kit
  • RNA sequencing kit
  • 5-HMC & 5-MC Analysis Kits& Reagents
  • Histones
  • Others
• Instruments
• Enzymes
  • Dna-Modifying Enzymes
  • Protein-Modifying Enzymes
  • Other Enzymes
• Services

Global Epigenetics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• DNA Methylation
• Histone Methylation
• Histone Acetylation
• Large non-coding RNA
• MicroRNA modification
• Chromatin structures

Global Epigenetics Market Size by Technique & CAGR (2025-2032)

• Market Overview
• NGS
• PCR & QPCR
• Mass Spectrometry
• Sonication
• Other Techniques

Global Epigenetics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Oncology
  • Solid tumors
  • Liquid tumors
• Non-oncology oncology
  • Inflammatory diseases
  • Metabolic diseases
  • Infectious diseases
  • Cardiovascular diseases
  • Others

Global Epigenetics Market Size by End-use & CAGR (2025-2032)

• Market Overview
• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users

Global Epigenetics Market Size & CAGR (2025-2032)

• North America (Product, Technology, Technique, Application, End-use)
  • US
  • Canada
• Europe (Product, Technology, Technique, Application, End-use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Technique, Application, End-use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Technique, Application, End-use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Technique, Application, End-use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• 10x Genomics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Active Motif, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zymo Research Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Element Biosciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dovetail Genomics LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Storm Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations